ISAAC STRONG: Open Payments
NPI 1497478697 · PROVO, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,890 in 94 payments from 14 companies in 2025. Trend: 2023 $1,920 · 2024 $1,563 · 2025 $1,890
Food & beverage: $1,884Education: $5
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $371 |
| Otsuka America Pharmaceutical, Inc. | 9 | $283 |
| Alkermes, Inc. | 12 | $224 |
| E.R. Squibb & Sons, L.L.C. | 17 | $223 |
| Neurocrine BioSciences, Inc. | 9 | $157 |
| Teva Pharmaceuticals USA, Inc. | 9 | $156 |
| Janssen Pharmaceuticals, Inc | 9 | $144 |
| ABBVIE INC. | 4 | $85 |
| Vanda Pharmaceuticals Inc. | 3 | $64 |
| Lundbeck LLC | 3 | $52 |
Products named: CAPLYTA, REXULTI, COBENFY, INGREZZA, ARISTADA, AUSTEDO XR, VRAYLAR, INVEGA SUSTENNA.
Industry payments across UT — which companies pay providers there.
